Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

499
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
499
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

179
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
179
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

152
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
152
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

135
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
135
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

919
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
919
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

2.6K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating thrombolysis into routine stroke care in a Ghanaian tertiary hospital, using the implementation research logic model (IRLM) as a guiding framework.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same author

Neuroworsening in traumatic brain injury: A consensus of the Latin American Brain Injury Consortium (LABIC) and the Latin American Federation of Neurosurgical Societies (FLANC) expert group.

Neurosurgical review·2026
Same author

Functional Outcomes After Intensive Blood Pressure Reduction in Deep and Lobar Intracerebral Hemorrhage.

Neurology·2026
Same author

Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions.

Stroke·2026
Same author

Resumption of Warfarin After Intracranial Hemorrhage in Patients With Mechanical Heart Valves: A Systematic Review and Meta-Analysis.

Journal of the American Heart Association·2026
Same author

A Decade of Game of Strokes at the International Stroke Conference: Reflections and Future Directions.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: Dec 12, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K

Tenecteplase for Acute Ischemic Stroke: Current Evidence and Practical Considerations.

Alejandro A Rabinstein1, Esteban Golombievski2, Jose Biller2

  • 1Department of Neurology, Mayo Clinic, 200 First Street SW, Mayo W8B, Rochester, MN, USA. rabinstein.alejandro@mayo.edu.

CNS Drugs
|August 14, 2020
PubMed
Summary

Tenecteplase shows promise for acute ischemic stroke treatment, offering advantages over alteplase, especially in severe cases and for rapid transport to stroke centers. Further research will clarify its role in stroke management.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.2K

Related Experiment Videos

Last Updated: Dec 12, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.2K

Area of Science:

  • Neurology
  • Pharmacology
  • Emergency Medicine

Background:

  • Acute ischemic stroke requires rapid intervention.
  • Alteplase is a current standard treatment, but has limitations.
  • Tenecteplase presents potential pharmacological and administration advantages.

Purpose of the Study:

  • To evaluate the efficacy and administration benefits of tenecteplase compared to alteplase for acute ischemic stroke.
  • To review current evidence supporting tenecteplase use in different stroke scenarios.
  • To discuss the optimal dosing and future regulatory considerations for tenecteplase.

Main Methods:

  • Review of recent randomized controlled trials comparing tenecteplase and alteplase.
  • Analysis of pharmacological properties and administration protocols.
  • Synthesis of clinical evidence regarding patient selection and outcomes.

Main Results:

  • Tenecteplase offers easier administration via a single bolus, beneficial for "drip and ship" and combined approaches.
  • Efficacy may be similar to alteplase in mild strokes.
  • Tenecteplase appears superior to alteplase in severe strokes with large vessel occlusion.
  • The 0.25 mg/kg dose is favored by cumulative evidence.

Conclusions:

  • Tenecteplase demonstrates significant advantages for acute ischemic stroke management, particularly in specific patient populations and scenarios.
  • While not yet FDA/EMA approved for stroke, ongoing trials and international experience are crucial for its future role.
  • Tenecteplase is a promising alternative or adjunct to alteplase, warranting further investigation and clinical adoption.